Valuation: Inventiva

Market Cap 794M 885M 732M 664M 1.26B 83B 1.29B 8.76B 3.49B 44.47B 3.32B 3.25B 141B P/E 2026 *
-4.89x
P/E 2027 * -7.15x
Enterprise Value 657M 733M 606M 550M 1.04B 68.7B 1.07B 7.25B 2.89B 36.81B 2.75B 2.69B 116B EV / Sales 2026 *
128x
EV / Sales 2027 * 162x
Free-Float
85.61%
Yield 2026 *
-
Yield 2027 * -
1 day+0.90%
1 week-5.35%
Current month+5.66%
1 month+17.48%
3 months-19.04%
6 months-26.15%
Current year-14.83%
1 week 3.18
Extreme 3.18
3.74
1 month 2.57
Extreme 2.57
3.76
Current year 2.57
Extreme 2.57
6.2
1 year 2.57
Extreme 2.57
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
12.7
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 01/10/2025
Director of Finance/CFO 59 22/04/2026
Chief Operating Officer - 31/08/2026
Director TitleAgeSince
Director/Board Member 76 01/02/2017
Director/Board Member 63 27/05/2019
Director/Board Member 52 01/05/2024
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Others

Executive/Senior Manager

50,000 0.0262%
10/1/26 Others

General Counsel

25,000 0.0131%
10/1/26 Others

Head of Human Resources

25,000 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
+0.90%-5.35%+1.97%-1.90% 885M
+0.01%+11.10%+60.83%+70.43% 68.32B
+1.22%+9.56%+15.97%+90.23% 60.26B
+0.24%+1.35%+23.78%+97.55% 55.86B
+1.60%+19.44%+28.80%+112.95% 48.43B
-1.32%+4.78%+29.15%+40.40% 45.34B
-3.54%-0.60%+207.76%+879.50% 41.76B
-3.33%+6.90%+22.78%+48.07% 34.5B
-2.19%-3.71%+90.94%+66.33% 33.8B
-1.77%+0.83%+46.57%-0.16% 25.96B
Average -0.82%+4.32%+52.86%+140.34% 42B
Weighted average by Cap. -0.67%+5.23%+55.19%+153.26%

Financials

2026 *2027 *
Net sales 5.13M 5.72M 4.73M 4.3M 8.13M 537M 8.36M 56.63M 22.56M 287M 21.48M 21.02M 909M 2.24M 2.5M 2.06M 1.87M 3.55M 234M 3.65M 24.7M 9.84M 125M 9.37M 9.17M 396M
Net income -159M -178M -147M -133M -253M -16.67B -260M -1.76B -701M -8.93B -667M -653M -28.23B -209M -233M -193M -175M -332M -21.88B -341M -2.31B -920M -11.72B -876M -857M -37.06B
Net Debt -137M -153M -126M -114M -217M -14.3B -223M -1.51B -601M -7.66B -572M -560M -24.22B -432M -482M -398M -362M -685M -45.19B -704M -4.77B -1.9B -24.21B -1.81B -1.77B -76.55B
Projected Income Statement - Annual - Inventiva
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
87
Date Price Change Volume
10/11/26 €3.360 +0.90% 480,123
09/11/26 €3.330 -2.06% 491,155
06/11/26 €3.400 +1.19% 696,697
05/11/26 €3.360 -5.22% 643,784
04/11/26 €3.545 -0.14% 1,006,801
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Inventiva
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.360EUR
Average target price
9.770EUR
Spread / Average Target
+190.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Inventiva